Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evidence for cPLA2 activation in Alzheimer's disease synaptic pathology.

Acta neuropathologica communications·2026

Same author

Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer's disease biomarkers.

Alzheimer's research & therapy·2025

Same author

Evidence for cPLA2 activation in Alzheimer's Disease Synaptic Pathology.

bioRxiv : the preprint server for biology·2025

Same author

Increased cerebrospinal fluid and plasma apoE glycosylation is associated with reduced levels of Alzheimer's disease biomarkers.

bioRxiv : the preprint server for biology·2025

Same author

Toward Systemic Lipofuscin Removal.

Rejuvenation research·2024

Same author

Exercise alters cortico-basal ganglia network metabolic connectivity: a mesoscopic level analysis informed by anatomic parcellation defined in the mouse brain connectome.

Brain structure & function·2023

Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026

Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026

Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026

Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026

Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026

Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Targeting clonal mutations with synthetic microbes.

Michael Renteln¹

¹The University of Southern California Keck School of Medicine, The United States.

Critical Reviews in Oncology/Hematology

|November 29, 2024

Summary

This summary is machine-generated.

A novel strategy, Oncolytic Vector Efficient Replication Contingent on Omnipresent Mutation Engagement (OVERCOME), targets clonal cancer mutations. This approach uses engineered bacteria that activate upon detecting mutations present in all cancer cells.

Keywords:

Achilles Therapeutics Cell-free circulating tumor DNA Clonal mutations Multiregion sequencing Multisample sequencing OVERCOME

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Published on: July 6, 2013

Related Experiment Videos

Last Updated: Jun 6, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria

Published on: July 6, 2013

Area of Science:

Oncology
Genomics
Bacteriology

Background:

Large-scale cancer genomics studies reveal clonal mutations in most tumors.
Clonal mutations, present in all cancer cells, are potential therapeutic targets.
Current targeted therapies for clonal mutations face feasibility challenges.

Purpose of the Study:

To propose a novel therapeutic strategy exploiting clonal cancer mutations.
To introduce the "Oncolytic Vector Efficient Replication Contingent on Omnipresent Mutation Engagement" (OVERCOME) approach.
To outline the potential use of bioengineered bacteria in cancer treatment.

Main Methods:

Conceptualization of the OVERCOME strategy.
Proposal of using a bioengineered facultative intracellular bacterium.
Design of bacteria with conditional attenuation reversal based on mutation detection.

Main Results:

The OVERCOME strategy offers a new way to target clonal mutations.
Engineered bacteria could be attenuated and activated by specific mutations.
This approach holds promise for personalized cancer therapy.

Conclusions:

The OVERCOME strategy presents a viable new avenue for cancer treatment.
Targeting clonal mutations with engineered bacteria could overcome current limitations.
Further research into bioengineered bacterial vectors is warranted.